IRB Study Number 23-890
Status Recruiting
Institute Taussig Cancer Institute
Description
4.1. Primary Objective
To identify participants with locally advanced (unresectable) or metastatic solid tumors that could potentially be eligible for a TScan treatment study.
4.2. Exploratory Objective
To assess the prevalence of HLA types and tumor antigen expression in participants with locally advanced (unresectable) or metastatic solid tumors.
Inclusion Criteria
Willing and able to provide written informed consent.
Male or female aged ≥18 years at the time of signing the informed consent.
Have one of the following histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor:
• Head and neck cancer
• Cervical cancer
• Non-small cell lung cancer
• Melanoma
• Ovarian cancer
• HPV+ anogenital cancers
Willing to provide a buccal swab for HLA testing
Willing to provide a saliva sample to use as a normal control for the LOH assay
Have access to an FFPE tumor block that is <6 months old or is willing to provide a fresh core-needle biopsy.
Exclusion Criteria
- Participants undergoing anticancer therapy with curative intent such as tumor surgical resection with or without neoadjuvant/adjuvant therapy, or definitive chemoradiation, unless they have locoregionally advanced disease and are expected to have a high risk of relapse after their curative intent therapy as determined by the treating investigator.
